Literature DB >> 25771386

Variants in Solute Carrier SLC26A9 Modify Prenatal Exocrine Pancreatic Damage in Cystic Fibrosis.

Melissa R Miller1, David Soave2, Weili Li2, Jiafen Gong1, Rhonda G Pace3, Pierre-Yves Boëlle4, Garry R Cutting5, Mitchell L Drumm6, Michael R Knowles3, Lei Sun7, Johanna M Rommens8, Frank Accurso9, Peter R Durie10, Harriet Corvol11, Hara Levy12, Marci K Sontag13, Lisa J Strug14.   

Abstract

OBJECTIVES: To test the hypothesis that multiple constituents of the apical plasma membrane residing alongside the causal cystic fibrosis (CF) transmembrane conductance regulator protein, including known CF modifiers SLC26A9, SLC6A14, and SLC9A3, would be associated with prenatal exocrine pancreatic damage as measured by newborn screened (NBS) immunoreactive trypsinogen (IRT) levels. STUDY
DESIGN: NBS IRT measures and genome-wide genotype data were available on 111 subjects from Colorado, 37 subjects from Wisconsin, and 80 subjects from France. Multiple linear regression was used to determine whether any of 8 single nucleotide polymorphisms (SNPs) in SLC26A9, SLC6A14, and SLC9A3 were associated with IRT and whether other constituents of the apical plasma membrane contributed to IRT.
RESULTS: In the Colorado sample, 3 SLC26A9 SNPs were associated with NBS IRT (min P=1.16×10(-3); rs7512462), but no SLC6A14 or SLC9A3 SNPs were associated (P>.05). The rs7512462 association replicated in the Wisconsin sample (P=.03) but not in the French sample (P=.76). Furthermore, rs7512462 was the top-ranked apical membrane constituent in the combined Colorado and Wisconsin sample.
CONCLUSIONS: NBS IRT is a biomarker of prenatal exocrine pancreatic disease in patients with CF, and a SNP in SLC26A9 accounts for significant IRT variability. This work suggests SLC26A9 as a potential therapeutic target to ameliorate exocrine pancreatic disease.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25771386      PMCID: PMC4530786          DOI: 10.1016/j.jpeds.2015.01.044

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  39 in total

1.  Functional characterization of three novel tissue-specific anion exchangers SLC26A7, -A8, and -A9.

Authors:  Hannes Lohi; Minna Kujala; Siru Makela; Eero Lehtonen; Marjo Kestila; Ulpu Saarialho-Kere; Daniel Markovich; Juha Kere
Journal:  J Biol Chem       Date:  2002-02-07       Impact factor: 5.157

2.  Neonatal screening for cystic fibrosis in Brittany, France: assessment of 10 years' experience and impact on prenatal diagnosis.

Authors:  V Scotet; M de Braekeleer; M Roussey; G Rault; P Parent; M Dagorne; H Journel; A Lemoigne; J P Codet; M Catheline; V David; A Chaventré; I Duguépéroux; C Verlingue; I Quéré; B Mercier; M P Audrézet; C Férec
Journal:  Lancet       Date:  2000-09-02       Impact factor: 79.321

3.  Immunoreactive Trypsinogen (IRT) as a Biomarker for Cystic Fibrosis: challenges in newborn dried blood spot screening.

Authors:  Bradford L Therrell; W Harry Hannon; Gary Hoffman; Jelili Ojodu; Philip M Farrell
Journal:  Mol Genet Metab       Date:  2012-02-28       Impact factor: 4.797

4.  Unraveling the complex genetic model for cystic fibrosis: pleiotropic effects of modifier genes on early cystic fibrosis-related morbidities.

Authors:  Weili Li; David Soave; Melissa R Miller; Katherine Keenan; Fan Lin; Jiafen Gong; Theodore Chiang; Anne L Stephenson; Peter Durie; Johanna Rommens; Lei Sun; Lisa J Strug
Journal:  Hum Genet       Date:  2013-09-22       Impact factor: 4.132

5.  [Evaluation of diagnosis and follow-up in screened children with cystic fibrosis in Normandy].

Authors:  J Brouard; I Lecoq; J F Viel; M Guillot; M Laurans; D Laroche; G Travert; J F Duhamel
Journal:  Arch Pediatr       Date:  2001-08       Impact factor: 1.180

6.  Molecular consequences of cystic fibrosis transmembrane regulator (CFTR) gene mutations in the exocrine pancreas.

Authors:  N Ahmed; M Corey; G Forstner; J Zielenski; L-C Tsui; L Ellis; E Tullis; P Durie
Journal:  Gut       Date:  2003-08       Impact factor: 23.059

7.  Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics.

Authors:  Linn Fagerberg; Björn M Hallström; Per Oksvold; Caroline Kampf; Dijana Djureinovic; Jacob Odeberg; Masato Habuka; Simin Tahmasebpoor; Angelika Danielsson; Karolina Edlund; Anna Asplund; Evelina Sjöstedt; Emma Lundberg; Cristina Al-Khalili Szigyarto; Marie Skogs; Jenny Ottosson Takanen; Holger Berling; Hanna Tegel; Jan Mulder; Peter Nilsson; Jochen M Schwenk; Cecilia Lindskog; Frida Danielsson; Adil Mardinoglu; Asa Sivertsson; Kalle von Feilitzen; Mattias Forsberg; Martin Zwahlen; IngMarie Olsson; Sanjay Navani; Mikael Huss; Jens Nielsen; Fredrik Ponten; Mathias Uhlén
Journal:  Mol Cell Proteomics       Date:  2013-12-05       Impact factor: 5.911

8.  Multiple apical plasma membrane constituents are associated with susceptibility to meconium ileus in individuals with cystic fibrosis.

Authors:  Lei Sun; Johanna M Rommens; Harriet Corvol; Weili Li; Xin Li; Theodore A Chiang; Fan Lin; Ruslan Dorfman; Pierre-François Busson; Rashmi V Parekh; Diana Zelenika; Scott M Blackman; Mary Corey; Vishal K Doshi; Lindsay Henderson; Kathleen M Naughton; Wanda K O'Neal; Rhonda G Pace; Jaclyn R Stonebraker; Sally D Wood; Fred A Wright; Julian Zielenski; Annick Clement; Mitchell L Drumm; Pierre-Yves Boëlle; Garry R Cutting; Michael R Knowles; Peter R Durie; Lisa J Strug
Journal:  Nat Genet       Date:  2012-05       Impact factor: 38.330

9.  Loss of Slc26a9 anion transporter alters intestinal electrolyte and HCO3(-) transport and reduces survival in CFTR-deficient mice.

Authors:  Xuemei Liu; Taolang Li; Brigitte Riederer; Henrike Lenzen; Lisa Ludolph; Sunil Yeruva; Biguang Tuo; Manoocher Soleimani; Ursula Seidler
Journal:  Pflugers Arch       Date:  2014-06-27       Impact factor: 3.657

10.  Evidence for a causal relationship between early exocrine pancreatic disease and cystic fibrosis-related diabetes: a Mendelian randomization study.

Authors:  David Soave; Melissa R Miller; Katherine Keenan; Weili Li; Jiafen Gong; Wan Ip; Frank Accurso; Lei Sun; Johanna M Rommens; Marci Sontag; Peter R Durie; Lisa J Strug
Journal:  Diabetes       Date:  2014-02-18       Impact factor: 9.461

View more
  21 in total

1.  The CFTR trafficking mutation F508del inhibits the constitutive activity of SLC26A9.

Authors:  Carol A Bertrand; Shalini Mitra; Sanjay K Mishra; Xiaohui Wang; Yu Zhao; Joseph M Pilewski; Dean R Madden; Raymond A Frizzell
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-03-30       Impact factor: 5.464

Review 2.  Recent advances in developing therapeutics for cystic fibrosis.

Authors:  Lisa J Strug; Anne L Stephenson; Naim Panjwani; Ann Harris
Journal:  Hum Mol Genet       Date:  2018-08-01       Impact factor: 6.150

3.  SLC26A9 is selected for endoplasmic reticulum associated degradation (ERAD) via Hsp70-dependent targeting of the soluble STAS domain.

Authors:  Patrick G Needham; Jennifer L Goeckeler-Fried; Casey Zhang; Zhihao Sun; Adam R Wetzel; Carol A Bertrand; Jeffrey L Brodsky
Journal:  Biochem J       Date:  2021-12-22       Impact factor: 3.857

4.  Separating the contributions of SLC26A9 and CFTR to anion secretion in primary human bronchial epithelia.

Authors:  Mads B Larsen; Jeannie J Choi; Xiaohui Wang; Michael M Myerburg; Raymond A Frizzell; Carol A Bertrand
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2021-10-20       Impact factor: 5.464

5.  Generation and functional characterization of epithelial cells with stable expression of SLC26A9 Cl- channels.

Authors:  Johanna J Salomon; Stephan Spahn; Xiaohui Wang; Joachim Füllekrug; Carol A Bertrand; Marcus A Mall
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-01-22       Impact factor: 5.464

6.  Increased expression of anion transporter SLC26A9 delays diabetes onset in cystic fibrosis.

Authors:  Anh-Thu N Lam; Melis A Aksit; Briana Vecchio-Pagan; Celeste A Shelton; Derek L Osorio; Arianna F Anzmann; Loyal A Goff; David C Whitcomb; Scott M Blackman; Garry R Cutting
Journal:  J Clin Invest       Date:  2020-01-02       Impact factor: 14.808

7.  Refining the continuum of CFTR-associated disorders in the era of newborn screening.

Authors:  H Levy; M Nugent; K Schneck; D Stachiw-Hietpas; A Laxova; O Lakser; M Rock; M K Dahmer; J Biller; S Z Nasr; M Baker; S A McColley; P Simpson; P M Farrell
Journal:  Clin Genet       Date:  2016-01-20       Impact factor: 4.438

Review 8.  Role of CFTR in epithelial physiology.

Authors:  Vinciane Saint-Criq; Michael A Gray
Journal:  Cell Mol Life Sci       Date:  2016-10-06       Impact factor: 9.261

9.  Cystic fibrosis gene modifier SLC26A9 modulates airway response to CFTR-directed therapeutics.

Authors:  Lisa J Strug; Tanja Gonska; Gengming He; Katherine Keenan; Wan Ip; Pierre-Yves Boëlle; Fan Lin; Naim Panjwani; Jiafen Gong; Weili Li; David Soave; Bowei Xiao; Elizabeth Tullis; Harvey Rabin; Michael D Parkins; April Price; Peter C Zuberbuhler; Harriet Corvol; Felix Ratjen; Lei Sun; Christine E Bear; Johanna M Rommens
Journal:  Hum Mol Genet       Date:  2016-10-15       Impact factor: 6.150

Review 10.  Novel Roles for Chloride Channels, Exchangers, and Regulators in Chronic Inflammatory Airway Diseases.

Authors:  Monica Sala-Rabanal; Zeynep Yurtsever; Kayla N Berry; Tom J Brett
Journal:  Mediators Inflamm       Date:  2015-11-03       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.